Calocurb, a New Zealand-based company that has created a safe, effective and clinically proven natural GLP-1 activator, has received two awards for its recent scientific and product achievements.
Calocurb, a New Zealand-based company that has created a safe, effective and clinically proven natural GLP-1 activator, has received two awards for its recent scientific and product achievements.The first honor, noted a company press release, was the Nutraingredients USA Award for Product of the Year – Botanical, which celebrates the best branded or own-label supplements, functional foods and beverages containing botanical ingredients.
Focusing on true innovation, long-term market success, and cutting-edge research, the Nutraingredients USA Awards honor the best and brightest in ingredients, finished products, companies, people and initiatives in the nutrition and dietary supplement industry.
Calocurb’s active ingredient is Amarasate®, a bitter extract from a specific New Zealand-grown hop flower that acts as a potent natural appetite suppressant. Supported by 14 years of research and $30 million in funding from the New Zealand government, Calocurb, powered by Amarasate, benefits from a clinically proven foundation as an effective and affordable natural GLP-1 activator that reduces hunger by 30%, cravings by 40% and caloric intake by an average of 18%.
“Calocurb is supported by a proper body of scientific research that not only identifies its mode of action but also differential effects in women, a population generally underrepresented in clinical trials,” said Stephen Daniells, PhD, Editor-in-Chief, Nutraingredients USA. “While bitter compounds have long been used as appetite suppressants, this Amarasate hops extract from New Zealand receives high marks for launching as a patented natural GLP-1 activator well before the run on semaglutide injectable drugs for weight management.”
Calocurb received its second award, this one from Nutrition Business Journal (NBJ) for Science & Innovation at the NBJ Summit award ceremony in Rancho Palos Verdes, California.
NBJ highlighted Calocurb’s commitment to real science, backed by clinical studies, as the reason it awarded the company the 2024 NBJ Award for Science & Innovation.
Amarasate, the active ingredient in Calocurb, is supported by three clinical studies and a fourth is underway, this one with 150 men and women measuring several biomarkers, including weight loss. The study will cost $2 million.
“We are delighted by the recognition we have received from such prestigious media outlets as Nutraingredients USA and NBJ,” said Calocurb CEO Sarah Kennedy. “We are in the fortunate position of having substantial clinical backing that will only continue to grow when we get the results of our fourth, and largest, clinical trial early next year. All of this ensures practitioners feel extremely confident about recommending Calocurb to their patients who either don’t have access to GLP-1 pharmaceuticals or are looking for an ‘off-ramp’ to those medications.”
About Calocurb and Amarasate
Amarasate® is a natural extract from a specific New Zealand bitter hop and is the active ingredient in Calocurb, which has been demonstrated in clinical trials to activate endogenous GLP-1, CCK and PYY release to reduce appetite by 30%, cravings by 40% and caloric intake by an average of 18% in one hour. For more information, visit calocurb.com.
